Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the hypoxanthine class of purine derivatives. It is an experimental compound with a molecular formula C18H22N6O3S and a molecular weight of approximately 402.5 g/mol. The compound has been studied as a potential inhibitor of cyclin-dependent kinase 2 (CDK2), which plays a key role in cell cycle regulation by controlling the transition from G1 to S phase. Inhibition of CDK2 is being explored for anticancer applications, but this specific molecule has not advanced beyond preclinical or early-stage research and is not approved for any indication.[1][2][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-benzenesulfonamide.